AGC to triple US capacity with $88mn investment

By hotmaillogin

Tokyo-based manufacturer of glass, chemicals and high tech materials, AGC Inc, announced today its plans to triple its biopharmaceutical production capacity in the United States through a major expansion of its subsidiary AGC Biologics.

While currently, AGC Biologics only possesses manufacturing infrastructure in Japan and Europe, plans were this week finalized to construct a major new facility in Seattle, Washington, as well as to expand the company’s current facilities in the city. The project will involve the installation of 12 additional 2,000L single-use mammalian cell bioreactors, as well as the construction of a new microbial contract development and manufacturing facility.

The new facilities are expected to start operating in July, 2020, and the total cost of the expansion is predicted to be in the realm of US$88mn.



This project continues a trend of expansion by AGC and its subsidiaries. In 2016 the company acquired German pharmaceutical manufacturer Biomeva, and CMC Biologics in 2017.

AGC intends to continue to pursue acquisition opportunities and to make capital investment in its synthetic and biopharmaceutical business,” said a company press release, “expected to exhibit significant growth in demand in the coming years, in order to continue providing customers in every region with globally consistent, top-level quality and service.


Featured Articles

PwC's Kathryn Kaminsky – the role of boards on social issues

As Vice Chair Trust Solutions Co-Leader at PwC, Kathryn Kaminsky says boards play an important role in helping businesses take action on social issues

Why your business needs a Chief Transformation Officer

Responsible for driving growth and change, the Chief Transformation Officer is the latest addition to the C-suite as business undergoes major change

12 top AI and ML trends for the enterprise in 2023 – Dataiku

With 2023 likely to be a huge year for AI, experts from AI platform provider Dataiku deliver their enterprise AI and ML trends for the year ahead

From NYC to Hong Kong, the rise of the private members' club

Leadership & Strategy

Meet the CEO: Jill Stelfox of Panzura, exclusive interview

Leadership & Strategy

The best Michelin-starred restaurants that are meat-free